The hepatic protective effect of ESGA was found to be dose-dependent and with no effect on adiposity, IR, and hyperglycemia, and act through modulating the expression and activities of hepatic transcription factors, including SREBP1/PPARα lipogenic, Nrf2/antioxidant, and the NF-κB/inflammatory axis. The gene discussed is SREBF1; the disease is Hyperglycemia.